[Osteoporosis and hormone replacement therapy].
Hormone replacement therapy prevents bone loss and the increase in bone resorption due to the hormone deficiency in oestrogen in postmenopausal women. The WHI (Women's Health Initiative) randomised, double-blind study against placebo, demonstrated that which all the epidemiological trials had already suggested: replacement therapy can reducing by around 30% the risk of fractures in postmenopausal women. Administration of hormone replacement therapy requires account being taken of (in view of the uncertainties regarding the anti-fracture effect of low dose therapy): the duration (in view of the absence of remnant effect of the product on bone loss and on the risk of fracture) and the benefit/risk ration (in view of the benefits demonstrated on climacteric disorders, but the increase in risk of breast cancer). The menopause is the occasion to assess individual risks, notably vascular and of fractures, taking into account the clinical risk factors and measurement of bone density.
Roux
Christian
C
Service de rhumatologie, Université René Descartes, Hôpital Cochin, 27, rue du Faubourg, St Jacques, 75014 Paris. christian.roux@cch.ap-hop-paris.fr
D015519:Bone Density / Q000502:physiology; D001862:Bone Resorption / Q000517:prevention & control; D001842:Bone and Bones / Q000378:metabolism; D004967:Estrogens / Q000502:physiology / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D020249:Hormone Replacement Therapy; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D012307:Risk Factors
D004967:Estrogens